NEW YORK - A potential HIV vaccine, looking to mirror mRNA COVID-19 vaccine technology, is showing promising results in phase 1 clinical trial testing, according to developers.Researchers at the International AIDS Vaccine Initiative and Scripps Research said the vaccine had success in producing rare immune cells that trigger antibodies to keep the virus from mutating.
The response was shown in 97% of participants who received the vaccine, according to the organizations."We believe this approach will be key to making an HIV vaccine and possibly important for making vaccines against other pathogens," Scripps Research Immunologist William Schief said in a statement.A health worker tests blood of a driver at a bus stand during a counselling and.